학술논문
Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma
Document Type
Article
Author
Byung-Keun Kim; 박소영; Ga-Young Ban; Mi-Ae Kim; Ji-Hyang Lee; Jin An; Ji-Su Shim; Youngsoo Lee; Ha-Kyeong Won; 이화영; 손경희; Sung-Yoon Kang; So Young Park; Hyun Lee; 김민혜; Jae-Woo Kwon; Sun-Young Yoon; Jae-Hyun Lee; Chin Kook Rhee; Ji-Yong Moon; Taehoon Lee; So Ri Kim; Jong-Sook Park; 김상헌; 박흥우; Jae Won Jeong; Sang-HoonKim; Young-Il Koh; Yeon Mok Oh; An-Soo Jang; Kwang Ha Yoo; 조유숙; Korean Academy of Asthma, Allergy, and Clinical Immunology
Source
Allergy, Asthma & Immunology Research, 12(6), pp.910-933 Nov, 2020
Subject
Language
English
ISSN
2092-7363
2092-7355
2092-7355
Abstract
Severe asthma (SA) presents in about 3%–5% of adult asthmatics and is responsible for over 60% of asthma-related medical expenses, posing a heavy socioeconomic burden. However, to date, a precise definition of or clear diagnostic criteria for SA have not been established, and therefore, it has been challenging for clinicians to diagnose and treat this disease. Currently, novel biologics targeting several molecules, such as immunoglobulin E, interleukin (IL)5, and IL4/IL13, have emerged, and many new drugs are under development. These have brought a paradigm shift in understanding the mechanism of SA and have also provided new treatment options. However, we need to agree on a precise definition of and its diagnostic criteria for SA. Additionally, it is necessary to explain the diagnostic criteria and to summarize current standard and additional treatment options. This review is an experts' opinion on SA from the Korean Academy of Asthma, Allergy, and Clinical Immunology, the Working Group on Severe Asthma, and aims to provide a definition of and diagnostic criteria for SA, and propose future direction for SA diagnosis and management in Korea.